Nkarta Inc (NKTX) is a clinical-stage biopharmaceutical company that focuses on developing therapies that use natural killer (NK) cells to fight cancer. The company's proprietary platform technology enables the expansion and activation of NK cells from multiple sources, including peripheral blood and cord blood. NK cells are part of the innate immune system and play an important role in the body's natural defenses against cancer and other diseases. Nkarta's lead product candidate, NKX101, is a potentially curative cell therapy for patients with relapsed or refractory hematological malignancies. The company is also developing other NK cell-based therapies for solid tumors and autoimmune diseases. Nkarta is headquartered in South San Francisco, California.
Nkarta Inc (NKTX) is a clinical-stage biopharmaceutical company that focuses on developing therapies that use natural killer (NK) cells to fight cancer. The company's proprietary platform technology enables the expansion and activation of NK cells from multiple sources, including peripheral blood and cord blood. NK cells are part of the innate immune system and play an important role in the body's natural defenses against cancer and other diseases. Nkarta's lead product candidate, NKX101, is a potentially curative cell therapy for patients with relapsed or refractory hematological malignancies. The company is also developing other NK cell-based therapies for solid tumors and autoimmune diseases. Nkarta is headquartered in South San Francisco, California.